Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 14 de 14
Filter
1.
BMC Genomics ; 20(1): 513, 2019 Jun 21.
Article in English | MEDLINE | ID: mdl-31226924

ABSTRACT

BACKGROUND: RNA sequencing offers advantages over other quantification methods for microRNA (miRNA), yet numerous biases make reliable quantification challenging. Previous evaluations of these biases have focused on adapter ligation bias with limited evaluation of reverse transcription bias or amplification bias. Furthermore, evaluations of the quantification of isomiRs (miRNA isoforms) or the influence of starting amount on performance have been very limited. No study had yet evaluated the quantification of isomiRs of altered length or compared the consistency of results derived from multiple moderate starting inputs. We therefore evaluated quantifications of miRNA and isomiRs using four library preparation kits, with various starting amounts, as well as quantifications following removal of duplicate reads using unique molecular identifiers (UMIs) to mitigate reverse transcription and amplification biases. RESULTS: All methods resulted in false isomiR detection; however, the adapter-free method tested was especially prone to false isomiR detection. We demonstrate that using UMIs improves accuracy and we provide a guide for input amounts to improve consistency. CONCLUSIONS: Our data show differences and limitations of current methods, thus raising concerns about the validity of quantification of miRNA and isomiRs across studies. We advocate for the use of UMIs to improve accuracy and reliability of miRNA quantifications.


Subject(s)
Sequence Analysis, RNA/standards , Animals , Bias , Humans , Mice , RNA Isoforms , RNA, Viral , Rats , Reproducibility of Results , Sequence Analysis, RNA/methods
2.
ACS Med Chem Lett ; 10(11): 1573-1578, 2019 Nov 14.
Article in English | MEDLINE | ID: mdl-32038769

ABSTRACT

A series of bicyclic pyridones were identified as potent inhibitors of catechol O-methyltransferase (COMT). Substituted benzyl groups attached to the basic nitrogen of the core scaffold gave the most potent inhibitors within this series. Rat pharmacokinetic studies showed medium to high levels of clearance for this series, but with high free fraction due to remarkably low levels of protein and tissue binding. In rat biomarker studies, levels of unbound drug exposure are seen in the brain, which exceed their respective IC50s, leading to changes in the levels of dopamine metabolites in a manner consistent with COMT inhibition.

3.
J Med Chem ; 61(21): 9647-9665, 2018 11 08.
Article in English | MEDLINE | ID: mdl-30272964

ABSTRACT

A series of 8-hydroxy quinolines were identified as potent inhibitors of catechol O-methyltransferase (COMT) with selectivity for the membrane-bound form of the enzyme. Small substituents at the 7-position of the quinoline were found to increase metabolic stability without sacrificing potency. Compounds with good pharmacokinetics and brain penetration were identified and demonstrated in vivo modulation of dopamine metabolites in the brain. An X-ray cocrystal structure of compound 21 in the S-COMT active site shows chelation of the active site magnesium similar to catechol-based inhibitors. These compounds should prove useful for treatment of many neurological and psychiatric conditions associated with compromised cortical dopamine signaling.


Subject(s)
Catechol O-Methyltransferase Inhibitors/chemistry , Catechol O-Methyltransferase Inhibitors/pharmacology , Catechol O-Methyltransferase/metabolism , Drug Design , Oxyquinoline/chemistry , Oxyquinoline/pharmacology , Animals , Brain/metabolism , Catechol O-Methyltransferase/chemistry , Catechol O-Methyltransferase Inhibitors/metabolism , Catechol O-Methyltransferase Inhibitors/pharmacokinetics , Male , Mice , Models, Molecular , Oxyquinoline/metabolism , Oxyquinoline/pharmacokinetics , Protein Conformation , Rats , Tissue Distribution
4.
PLoS One ; 12(11): e0188852, 2017.
Article in English | MEDLINE | ID: mdl-29186181

ABSTRACT

Inositol pyrophosphates have been implicated in a wide range of cellular processes. Inositol hexakisphosphate kinase 1 catalyzes the pyrophosphorylation of inositol hexakisphosphate into inositol 5-diphospho-1,2,3,4,6-pentakisphosphate which is important in numerous areas of cell physiology such as DNA repair and glucose homeostasis. Furthermore, inositol 5-diphospho-1,2,3,4,6-pentakisphosphate is implicated in the pathology of diabetes and other human diseases. As such there is a demonstrated need in the field for a robust chemical probe to better understand the role of inositol hexakisphosphate kinase 1 and inositol pyrophosphate in physiology and disease. To aid in this effort we developed a homogenous coupled bioluminescence assay for measuring inositol hexakisphosphate kinase 1 activity in a 384-well format (Z' = 0.62±0.05). Using this assay we were able to confirm the activity of a known inositol hexakisphosphate kinase 1 inhibitor N2-(m-trifluorobenzyl), N6-(p-nitrobenzyl)purine. We also screened the Sigma library of pharmacologically active compounds at 10µM concentration and found 24 hits. Two of the most potent compounds were found to have an IC50 less than 5µM. The use of this high-throughput assay will accelerate the field towards the discovery of a potent inositol hexakisphosphate kinase 1 inhibitor.


Subject(s)
Phosphotransferases (Phosphate Group Acceptor)/metabolism , Adenosine Triphosphate/metabolism , Electrophoresis, Polyacrylamide Gel , High-Throughput Screening Assays , Humans , Kinetics
5.
J Biomol Screen ; 21(5): 490-5, 2016 Jun.
Article in English | MEDLINE | ID: mdl-26582803

ABSTRACT

Catechol-O-methyltransferase (COMT) plays an important role in the deactivation of catecholamine neurotransmitters and hormones. Inhibitors of COMT, such as tolcapone and entacapone, are used clinically in the treatment of Parkinson's disease. Discovery of novel inhibitors has been hampered by a lack of suitable assays for high-throughput screening (HTS). Although assays using esculetin have been developed, these are affected by fluorescence, a common property of catechol-type compounds. We have therefore evaluated a new homogenous time-resolved fluorescence (HTRF)-based assay from CisBio (Codolet, France), which measures the production of S-adenosyl-L-homocysteine (SAH). The assay has been run in both HTS and medium-throughput screening (MTS) modes. The assay was established using membranes expressing human membrane-bound COMT and was optimized for protein and time to give an acceptable signal window, good potency for tolcapone, and a high degree of translation between data in fluorescence ratio and data in terms of [SAH] produced. pIC50 values for the hits from the HTS mode were determined in the MTS mode. The assay also proved suitable for kinetic studies such as Km,app determination.


Subject(s)
Catechol O-Methyltransferase Inhibitors/isolation & purification , Catechol O-Methyltransferase/chemistry , High-Throughput Screening Assays/methods , Small Molecule Libraries/isolation & purification , Benzophenones/therapeutic use , Catechol O-Methyltransferase/drug effects , Catechol O-Methyltransferase Inhibitors/chemistry , Catechol O-Methyltransferase Inhibitors/therapeutic use , Catechols/therapeutic use , Humans , Kinetics , Nitrophenols/therapeutic use , Parkinson Disease/drug therapy , S-Adenosylhomocysteine/chemistry , Small Molecule Libraries/chemistry , Small Molecule Libraries/therapeutic use , Tolcapone
6.
Invest Ophthalmol Vis Sci ; 54(3): 1887-97, 2013 Mar 28.
Article in English | MEDLINE | ID: mdl-23422828

ABSTRACT

PURPOSE: We compared the cellular phenotypes and studied the role of autophagy in the pathogenesis of Fuchs endothelial corneal dystrophy (FECD) using two α2 collagen VIII (Col8a2) knock-in mouse models and human FECD tissues. METHODS: In vivo corneal endothelial cell (CEC) counts and morphology were analyzed by clinical confocal microscopy. Ultrastructural analysis of CECs was performed by transmission electron microscopy. Real-time PCR and Western blotting were performed using total RNA, and protein extracted from mouse CECs and human CECs obtained from FECD and autopsy patients. RESULTS: Both Col8a2 mouse models exhibited hallmarks of FECD; however, the Col8a2(L450W/L450W) mice exhibited a milder phenotype compared to the Col8a2(Q455K/Q455K) mice. Both models exhibited upregulation of the unfolded protein response (UPR) as evidenced by dilated rough endoplasmic reticulum (RER), and upregulation of UPR-associated genes and proteins. Real-time PCR of Col8a2(L450W/L450W) and Col8a2(Q455K/Q455K) CECs at 40 weeks revealed a 2.1-fold (P < 0.05) and a 5.2-fold (P < 0.01) upregulation of the autophagy marker Dram1, respectively. Real-time PCR of human FECD endothelium revealed a 10.4-fold upregulation of DRAM1 (P < 0.0001) compared to autopsy controls. CONCLUSIONS: The Col8a2(L450W/L450W) and Col8a2(Q455K/Q455K) mouse models of FECD showed distinct endothelial cell phenotypes. Dram1 was associated with activation of the UPR and increased autophagy. Overexpression of this gene in mouse and human FECD endothelial cells suggested a role for altered autophagy in this disease.


Subject(s)
Autophagy/physiology , Collagen Type VIII/genetics , Fuchs' Endothelial Dystrophy/genetics , Fuchs' Endothelial Dystrophy/pathology , Animals , Autophagy/genetics , Blotting, Western , Collagen Type VIII/physiology , Disease Models, Animal , Endothelial Cells/pathology , Endothelium, Corneal/metabolism , Gene Knock-In Techniques , Genotype , Mice , Mice, Transgenic , Microscopy, Electron, Transmission , Phenotype , Real-Time Polymerase Chain Reaction
7.
Hum Mol Genet ; 21(2): 384-93, 2012 Jan 15.
Article in English | MEDLINE | ID: mdl-22002996

ABSTRACT

Fuchs endothelial corneal dystrophy (FECD) is a leading indication for corneal transplantation. FECD is characterized by progressive alterations in endothelial cell morphology, excrescences (guttae) and thickening of the endothelial basement membrane and cell death. Ultimately, these changes lead to corneal edema and vision loss. Due to the lack of vision loss in early disease stages and the decades long disease course, early pathophysiology in FECD is virtually unknown as studies of pathologic tissues have been limited to end-stage tissues obtained at transplant. The first genetic defect shown to cause FECD was a point mutation causing a glutamine to lysine substitution at amino acid position 455 (Q455K) in the alpha 2 collagen 8 gene (COL8A2) which results in an early onset form of the disease. Homozygous mutant knock-in mice with this mutation (Col8a2(Q455K/Q455K)) show features strikingly similar to human disease, including progressive alterations in endothelial cell morphology, cell loss and basement membrane guttae. Ultrastructural analysis shows the predominant defect as dilated endoplasmic reticulum (ER), suggesting ER stress and unfolded protein response (UPR) activation. Immunohistochemistry, western blotting, quantitative reverse transcriptase polymerase chain reaction and terminal deoxynucleotidyl transferase 2-deoxyuridine, 5-triphosphate nick end-labeling analyses support UPR activation and UPR-associated apoptosis in the Col8a2(Q455K/Q455K) mutant corneal endothelium. This study confirms the Q455K substitution in the COL8A2 gene as being sufficient to cause FECD in the first mouse model of this disease and supports the role of the UPR and UPR-associated apoptosis in the pathogenesis of FECD caused by COL8A2 mutations.


Subject(s)
Apoptosis , Collagen Type VIII/genetics , Disease Models, Animal , Endothelium, Corneal/metabolism , Fuchs' Endothelial Dystrophy/pathology , Animals , Endothelium, Corneal/pathology , Fuchs' Endothelial Dystrophy/genetics , Fuchs' Endothelial Dystrophy/metabolism , Mice , Mice, Transgenic , Microscopy, Electron , Mutation , Protein Denaturation
8.
Exp Eye Res ; 83(4): 890-6, 2006 Oct.
Article in English | MEDLINE | ID: mdl-16777092

ABSTRACT

The purpose of this study was to characterize age-associated changes in the corneal endothelium and Descemet's membrane (DM) in C57BL/6 mice, an inbred strain commonly used as a genetic disease model. Corneas from mice aged 2 weeks to 24 months were studied. Light microscopy was used to assess central endothelial cell density, area, and morphology. Transmission electron microscopy was used to assess thickness and ultrastructural features of DM. Central corneal endothelial cell density showed a rapid decline from 5,232+/-892 cells/mm(2) (mean+/-S.D.) at 2 weeks to 2,532+/-112 cells/mm(2) at 16 weeks of age. Thereafter, cell density declined more slowly, reaching 2,004+/-134 cells/mm(2) at 24 months of age. DM thickness showed an approximately linear increase from 1.12+/-0.22 microm (mean+/-S.D.) at 2 weeks to 4.19+/-1.17 microm at 24 months of age. DM in 2 and 6 week age groups was composed entirely of material with an electron dense, periodic banding pattern. Sixteen week, 12 month, and 24 month age groups exhibited an additional, progressively thicker, homogeneous layer lacking periodic banding. The observed age-dependent thickening of DM was predominantly due to accumulation of the posterior, non-banded layer. In C57BL/6 mice, central endothelial cell density declines with age and DM progressively thickens due to accumulation of a posterior, non-banded portion. These age-associated changes are strikingly similar to observations in humans and thus further support the potential usefulness of the mouse model for studying disorders of the corneal endothelium and Descemet's membrane.


Subject(s)
Aging/pathology , Descemet Membrane/ultrastructure , Endothelium, Corneal/ultrastructure , Animals , Cell Count , Disease Models, Animal , Mice , Mice, Inbred C57BL , Microscopy, Electron
9.
Int J Cancer ; 111(3): 415-7, 2004 Sep 01.
Article in English | MEDLINE | ID: mdl-15221970

ABSTRACT

PCNA and esophagin have been implicated in the multistep process of carcinogenesis, but simultaneous characterization of these proteins in the early stages of esophageal neoplastic progression has yet to be undertaken. In morphologically normal esophageal epithelium, esophagin stains the granular layer cells, principally in their cell membrane portions. PCNA, in contrast, stains the nuclei of cells in the parabasal and basal layers. We examined 201 regions from 47 patients that represented different stages of esophageal neoplasia, comprising 34 areas of normal mucosa, 18 of dysplasia in squamous epithelium (DYS/SC), 39 squamous cell carcinoma (SCCA), 29 areas of Barrett's esophagus, 48 of Barrett's dysplasia (DYS/BAR) and 33 areas of adenocarcinoma (AC). The immunostaining patterns of esophagin and PCNA were evaluated and graded for level of expression. There was loss of esophagin expression in the high- and low-grade dysplasias compared to normal epithelia. In the squamous dysplasias, there was more intense staining (of esophagin) in the atypical nuclei and superficial squamous epithelial cells than in the basal cells. PCNA staining was increased in intensity in the high-grade dysplasias relative to normal basal layer cells. Combined analysis of esophagin and PCNA appears to reveal an inverse relationship between proliferation and differentiation during esophageal neoplastic progression. Moreover, this combined staining approach also offers promise for detecting esophageal cancer in early, precancerous stages.


Subject(s)
Biomarkers, Tumor/analysis , Carcinoma, Squamous Cell/pathology , Esophageal Neoplasms/pathology , Peptides/analysis , Proliferating Cell Nuclear Antigen/analysis , Barrett Esophagus/pathology , Diagnosis, Differential , Disease Progression , Humans , Immunohistochemistry , Neoplasm Staging , Phosphoproteins/analysis , Proline-Rich Protein Domains , Reference Values , Respiratory Mucosa/cytology , Respiratory Mucosa/pathology
10.
Lab Invest ; 83(12): 1867-71, 2003 Dec.
Article in English | MEDLINE | ID: mdl-14691305

ABSTRACT

The activin type II receptorgene (ACTRII) is mutated in 58.1% of microsatellite-unstable (MSI-H) colorectal cancers and is a close relative of the TGFbeta-1 type II receptor, which is known to be involved in both MSI-H and non-MSI-H colorectal carcinogenesis. We therefore sought to determine whether ACTRII was involved in non-MSI-H colorectal cancers. We evaluated ACTRII inactivation by allelic deletion, loss of mRNA expression, or somatic mutation in 51 non-MSI-H colon cancers. Loss of heterozygosity (LOH) at the ACTRII locus (2q23.1) was found in 9 (17.6%) of 51 primary tumors. Loss of ACTRII mRNA expression was seen in one (14.3%) of the seven LOH-positive primary tumors from which total RNA was available. We also performed DNA sequencing analysis of tumors showing LOH. One LOH-positive primary tumor exhibited a novel germline missense sequence alteration (amino acid substitution, 117 Ile to Phe) that was not found in 23 additional normal individuals, implying that this alteration is not a frequent polymorphism. We conclude that ACTRII is probably involved in both non-MSI-H and MSI-H colorectal carcinogenesis, but more frequently in the latter subgroup.


Subject(s)
Activin Receptors, Type II/genetics , Adenocarcinoma/genetics , Colorectal Neoplasms/genetics , Loss of Heterozygosity , Mutation, Missense , Activin Receptors, Type II/metabolism , Adenocarcinoma/metabolism , Adenocarcinoma/pathology , Colorectal Neoplasms/metabolism , Colorectal Neoplasms/pathology , DNA Mutational Analysis , DNA, Neoplasm/analysis , Gene Expression Regulation, Neoplastic , Humans , Microsatellite Repeats/genetics , RNA, Messenger/metabolism , RNA, Neoplasm/analysis , Reverse Transcriptase Polymerase Chain Reaction
11.
Oncogene ; 22(3): 467-70, 2003 Jan 23.
Article in English | MEDLINE | ID: mdl-12545169

ABSTRACT

Frequent loss of heterozygosity (LOH) on human chromosome 7q31 has been reported in numerous malignancies. Suppressor of tumorigenicity 7 (ST7) has been identified as a candidate tumor suppressor gene in this region. To identify whether 7q31 and genetic alterations of ST7 were involved in human esophageal carcinogenesis, we performed LOH mapping of a 5.4 cM region at 7q31-q35 in 43 primary esophageal carcinomas, as well as mutational analyses of the ST7 gene in tumors with LOH in this region. Of 43 tumors, 12 (28%) showed LOH at 7q31-q35. These included four (22%) of 18 squamous cell carcinomas and eight (32%) of 25 adenocarcinomas. The peak LOH locus was D7S480, lying 4.2 Mb telomeric to ST7 and showing LOH in eight of 37 informative tumors, or 22%. No mutations were found in the entire coding or flanking intronic regions of the ST7 gene among 12 tumors with 7q-LOH. In addition, quantitative RT-PCR analyses of ST7 mRNA expression levels in 11/13 normal-tumor pairs failed to show more than a 50% decrease in tumor ST7 mRNA relative to matched normal tissues. These data suggest that LOH at 7q31-q35 is involved in the origin or progression of at least a subset of esophageal carcinomas, but that ST7 is not the target gene of this somatic event.


Subject(s)
Carcinoma/genetics , Esophageal Neoplasms/genetics , Loss of Heterozygosity , Mutation , Proteins/genetics , Tumor Suppressor Proteins , Adenocarcinoma/genetics , Chromosomes, Human, Pair 7 , DNA, Intergenic , Gene Expression Regulation, Neoplastic , Humans , Introns , Neoplasms, Squamous Cell/genetics , Quantitative Trait Loci , Reference Values , Sequence Analysis, DNA
12.
Cancer Res ; 62(23): 6820-2, 2002 Dec 01.
Article in English | MEDLINE | ID: mdl-12460892

ABSTRACT

The HPP1 gene was cloned as a frequently methylated gene in hyperplastic polyps of the colon. It has been shown that HPP1 expression is silenced by HPP1 gene hypermethylation in sporadic colorectal cancers. To determine the role of HPP1 in ulcerative colitis (UC)-associated carcinogenesis, the prevalence of HPP1 methylation was investigated in three different histological stages of UC-associated carcinogenesis (non-neoplastic UC colon, dysplasia, and carcinoma). Quantitative methylation-specific PCR and quantitative reverse transcription-PCR were used to determine HPP1 gene methylation and expression levels, respectively. HPP1 methylation was observed in 24 of 48 (50%) adenocarcinomas and in 4 of 10 (40%) dysplasias. In contrast, no non-neoplastic UC mucosa showed HPP1 methylation. HPP1 expression in the HCT116 colon cancer cell line was restored after treatment with the demethylating agent 5-aza-2'-deoxycytidine. In conclusion, our data suggest that methylation of HPP1 is a relatively common early event in UC-associated carcinogenesis. HPP1 offers potential as a biomarker for the early detection of cancer or dysplasia in UC.


Subject(s)
Colitis, Ulcerative/genetics , Colorectal Neoplasms/genetics , DNA Methylation , Membrane Proteins/genetics , Neoplasm Proteins/genetics , Colitis, Ulcerative/complications , Colitis, Ulcerative/pathology , Colorectal Neoplasms/etiology , Colorectal Neoplasms/pathology , Disease Progression , Humans , Membrane Proteins/biosynthesis , Microsatellite Repeats/genetics , Neoplasm Proteins/biosynthesis , RNA, Messenger/biosynthesis , RNA, Messenger/genetics , Reverse Transcriptase Polymerase Chain Reaction , Tumor Cells, Cultured
13.
Cancer Res ; 62(13): 3641-5, 2002 Jul 01.
Article in English | MEDLINE | ID: mdl-12097267

ABSTRACT

Microsatellite instability (MSI) within coding regions causes frameshift mutations (FSMs). This type of mutation may inactivate tumor suppressor genes in cancers with frequent MSI (MSI-H cancers). To identify novel FSMs in gastric carcinogenesis in an unbiased and comprehensive manner, we screened for this type of mutation at 154 coding region repeat loci in 18 MSI-H gastric cancers. We also compared FSM rates and spectra in MSI-H gastric versus colorectal cancers. Thirteen novel loci showed FSMs in >20% of gastric tumors. Novel loci with the highest mutation frequencies included the activin type 2 receptor gene (44.4%), DKFZp564K112 (a homologue of the Drosophila tumor suppressor gene multi-sex-combs; 41.2%), and an endoplasmic reticulum chaperone protein gene SEC63 (37.5%). The mutational spectra for genes with high mutation frequencies were also significantly different between MSI-H gastric and colorectal cancers.


Subject(s)
Frameshift Mutation , Microsatellite Repeats/genetics , Stomach Neoplasms/genetics , Colorectal Neoplasms/genetics , Humans
14.
Cancer Res ; 62(12): 3493-7, 2002 Jun 15.
Article in English | MEDLINE | ID: mdl-12067993

ABSTRACT

cDNAmicroarrays, combined with bioinformatics analyses, are becomingincreasingly used in current medical research. Existing analytic methods,particularly those that are unsupervised, often have difficulty recognizing subtle differences among predefined subgroups. In contrast, supervised methods, such as Artificial Neural Networks (ANNs), are able to recognize subtly different biological entities. We applied ANNs in a proof-of-principle study of cDNA microarray data in esophageal cancer (CA) and premalignancy. cDNA microarrays, each containing 8064 clones, were hybridized to RNAs from 22 esophageal lesions, including 14 Barrett's esophagus (BA) metaplasias and 8 esophageal carcinomas (3 squamous cell carcinomas and 5 adenocarcinomas). Scanned cDNA microarray data were analyzed using the bioinformatics software Cluster/TreeView, Significance Analysis of Microarrays (SAM), and ANNs. Cluster analysis based on all 8064 clones on the microarrays was unable to correctly distinguish BA specimens from CA specimens. SAM then selected 160 differentially expressed genes between Barrett's and cancer. Cluster analysis based on this reduced set still misclassified 2 Barrett's as cancers. The ANN was trained on 12 samples and tested against the remaining 10 samples. Using the 160 selected genes, the ANN correctly diagnosed all 10 samples in the test set. Finally, the 160 genes selected by SAM may merit further study as biomarkers of neoplastic progression in the esophagus, as well as in elucidating pathological mechanisms underlying BA and CA.


Subject(s)
Barrett Esophagus/genetics , Esophageal Neoplasms/genetics , Neural Networks, Computer , Adenocarcinoma/genetics , Adenocarcinoma/metabolism , Barrett Esophagus/metabolism , Carcinoma, Squamous Cell/genetics , Carcinoma, Squamous Cell/metabolism , Cluster Analysis , Computational Biology/methods , Esophageal Neoplasms/metabolism , Gene Expression Profiling , Humans , Multigene Family , Oligonucleotide Array Sequence Analysis
SELECTION OF CITATIONS
SEARCH DETAIL
...